Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-EARLY open-label extension of acoramidis in variant transthyretin amyloid cardiomyopathy
2024-513676-18-00Phase 3Authorised
- Sponsor
- Eidos Therapeutics
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM) and transthyretin amyloidosis (ATTR), sponsored by Eidos Therapeutics. Primary endpoint: Safety and tolerability. Planned start Oct 2025; status: authorised.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on 2024-513676-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513676-18-00.